RAD 150 (TLB 150) SARM POWDER – 1000MG / 1 GRAM
Only 4 left in stock
Only 4 left in stock
RAD-150 Powder (aka TLB-150 or RAD-140 Ester)
Synthetic chemists are increasingly reevaluating how to push the boundaries of SARM development to maximize potency, biodistribution, half-life, and tissue selectivity, while still minimizing off-target/adverse effects. The most cutting-edge research SARMs undergoing development are those which are rationally designed using the cumulative pharmacological insights from over 30 years of androgen research, rather than discovered via screening or dumb luck, which was typical of SARM development early on.
Please note that RAD-150 (TLB-150) was not developed by Radius Health, Inc. While the official name is TLB-150, it was coined RAD-150 due to its structural similarity to RAD-140, its parent compound.
This information is for educational purposes only. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).
 G. A. Brown, M. Vukovich, and D. S. King, “Testosterone prohormone supplements,” Medicine and Science in Sports and Exercise. 2006.
 T. N. Ziegenfuss, J. M. Berardi, L. M. Lowery, and J. Antonio, “Effects of prohormone supplementation in humans: A review,” Can. J. Appl. Physiol., 2002.
 F. F. Ip, I. Di Pierro, R. Brown, I. Cunningham, D. J. Handelsman, and P. Y. Liu, “Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets,” Eur. J. Endocrinol., 2010.
 A. A. Yassin and M. Haffejee, “Testosterone depot injection in male hypogonadism: a critical appraisal.,” Clinical interventions in aging. 2007.
 K. L. Johansen, K. Mulligan, and M. Schambelan, “Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial,” J. Am. Med. Assoc., 1999.
 K. L. Johansen, P. L. Painter, G. K. Sakkas, P. Gordon, J. Doyle, and T. Shubert, “Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial,” J. Am. Soc. Nephrol., 2006.
 J. H. MacDonald, S. M. Marcora, M. M. Jibani, M. J. Kumwenda, W. Ahmed, and A. B. Lemmey, “Nandrolone decanoate as anabolic therapy in chronic kidney disease: A randomized phase II dose-finding study,” Nephron - Clin. Pract., 2007.
 C. Hassager, J. Pødenphant, B. J. Riis, J. S. Johansen, J. Jytte, and C. Christiansen, “Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women,” Metabolism, 1989.
 “Anabolics - William Llewellyn - Google Books.” [Online]. Available: https://books.google.com/books?id=afKLA-6wW0oC&pg=PT402#v=onepage&q&f=false. [Accessed: 17-Jul-2020].
 R. S. Gudde and J. R. Addicam, “Comparative evaluation of testosterone release and its derivatives in adult male monkeys,” Open Androl. J., 2012.
 T. Piper et al., “Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls,” Drug Test. Anal., 2018.
Shipping Conditions: Ambient temperature.
|Dimensions||3 × 3 × 5 in|